Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,990 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influenza A(H1N1)pdm09 during air travel.
Neatherlin J, Cramer EH, Dubray C, Marienau KJ, Russell M, Sun H, Whaley M, Hancock K, Duong KK, Kirking HL, Schembri C, Katz JM, Cohen NJ, Fishbein DB. Neatherlin J, et al. Among authors: russell m. Travel Med Infect Dis. 2013 Mar-Apr;11(2):110-8. doi: 10.1016/j.tmaid.2013.02.004. Epub 2013 Mar 21. Travel Med Infect Dis. 2013. PMID: 23523241 Free PMC article.
The Winding Road from Origin to Emergence (of Life).
Nitschke W, Farr O, Gaudu N, Truong C, Guyot F, Russell MJ, Duval S. Nitschke W, et al. Among authors: russell mj. Life (Basel). 2024 May 9;14(5):607. doi: 10.3390/life14050607. Life (Basel). 2024. PMID: 38792628 Free PMC article. Review.
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
Pandit-Taskar N, O'Donoghue JA, Chetty D, Max S, Wanik D, Ilovich O, Russell M, Nyima T, Divgi CR, Yu M, Morris MJ. Pandit-Taskar N, et al. Among authors: russell m. J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416. Online ahead of print. J Nucl Med. 2024. PMID: 38782459
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
2,990 results